Animalcare Group Plc (ANCR) fair value: what the stock is really worth
As of Jul 30, 2026: fair value of Animalcare Group Plc £3.44, price £3.35, upside +2.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Animalcare Group Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range £1.38 – £3.85 · fair‑value band £2.42 – £4.48 · the £3.35 price screens below the £3.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Animalcare Group in your weekly email
Every Wednesday you see whether Animalcare Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments.
Show more
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments. The company offers Orozyme, an enzymatic toothpaste for dental care in cats and dogs; Danilon, an oral treatment for pain in horses; Dinalgen, an injectable treatment for pain in cattle, pigs, and horses; Aqupharm, a dehydration treatment for cats, dogs, cattle, goats, horses, pigs, rabbits, and sheep; Ulcershield, a treatment and prevention of gastric ulcers in horses; Daxocox, a treatment of osteoarthritis pain and inflammation in dogs; Plaqtiv+, a biofilm-based dental care for cats and dogs; Thiamacare, a treatment for hyperthyroidism in cats; Hemo, an injectable nutritional solution for horses; and Cosequin, a complementary feed for dogs and cats to strengthen and protect joints. It also provides nutritional supplements for the equine market; and professional support services to equine veterinarians. The company exports its products to approximately 45 countries. It has a collaboration with 272Bio to develop and commercialize a novel biological treatment for equine sweet itch. Animalcare Group plc is based in York, the United Kingdom.
Stock analysis
Animalcare Group Plc (ANCR) currently trades at £3.35, while our model-based Fair Value estimate is £3.44, so the stock looks roughly fairly valued today (gap 2.6%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £2.59 per share, and 5 of the 26 models we run sit above the £3.35 price.
Bear case: the Dividend Discount group reads lowest at £0.6600, and 21 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: £2.42 (bear) to £4.48 (bull), the price of £3.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Animalcare Group Plc reported revenue of £89.1M in FY2025 versus £74.0M in FY2021, a compound +4.7%/yr. Reported net income was £5.1M in FY2025.
Key figures
Market cap 233M GBX · P/E ratio 47.9 · P/S ratio 2.73 · EPS (TTM) £0.0700 · Dividend yield 0.7% · Net margin 5.7% · Return on equity 4.5% · Return on assets (EBIT) 4.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 57% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 3%, ANCR screens cheaper than that median.
Fair Value models
Bear £2.42Fair Value £3.44Bull £4.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (£0.0480 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+20.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +20.7% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+86.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+85.9%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.79.8% vs 5.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 8%
2025 sits 126% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +12.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+2.7% · Above median
Profitability
Return on equity (TTM)4.5% · Below median
Return on assets2.6% · Below median
Net margin (TTM)5.7% · Below median
Operating margin (TTM)4.8% · Below median
Growth and dividend
Revenue growth21.5% · Top 25%
Dividend yield (TTM)0.7% · Below median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)47.9× · Priciest 25%
P/B2.03× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Animalcare Group Plc Fair Value". https://www.fairvalue-calculator.com/stock/ANCR
Frequently asked questions
Is Animalcare Group Plc (ANCR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £3.44 versus the last price from Jul 30, 2026 of £3.35, about +3% upside (fairly valued).
What is the fair value of ANCR?
Our model-based fair value for Animalcare Group Plc is £3.44 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 30, 2026): £3.35.
What is the quality score of ANCR?
Animalcare Group Plc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Animalcare Group Plc (ANCR)?
Our model-based price target is the fair value of £3.44 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario £2.42, optimistic scenario £4.48. It is a calculation from audited fundamentals, not an analyst target.
What is the Animalcare Group Plc stock forecast for 2026?
Our models put fair value at £3.44, about +3% upside versus the last price from Jul 30, 2026 of £3.35 (fairly valued). Cautious scenario £2.42, optimistic scenario £4.48. The calculation is refreshed regularly with new filings.
What is the revenue of Animalcare Group Plc (ANCR)?
Animalcare Group Plc reported trailing-twelve-month revenue of about £89.1M (latest available figure, as of Sep 24, 2026).
Does Animalcare Group Plc pay a dividend?
Animalcare Group Plc currently shows a dividend yield of about 0.66% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Animalcare Group Plc (ANCR)?
For today's price to be fair in a discounted-cash-flow model, Animalcare Group Plc would have to grow free cash flow by +14.6 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ANCR use?
Our models discount Animalcare Group Plc at 10.8 %: a base by market capitalisation (small), damped by beta 0.67, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Animalcare Group Plc that is +14.6 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Animalcare Group Plc (ANCR) delivered so far?
Over the past 5 years revenue at Animalcare Group Plc grew +4.8 % a year. The price currently implies +14.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Animalcare Group Plc (ANCR) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into Animalcare Group Plc (+14.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Animalcare Group Plc (ANCR)?
The free-cash-flow yield on the price is 4.60 %: that much free cash flow Animalcare Group Plc produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Animalcare Group Plc (ANCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Animalcare Group Plc it is £3.44 per share (as of Sep 24, 2026), against a price of £3.35. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Animalcare Group Plc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ANCR trades below its calculated fair value: price £3.35, fair value £3.44, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANCR?
No. The price is what the market pays today (£3.35); the fair value is what the company's own numbers justify (£3.44). For Animalcare Group Plc the two are £0.0900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Animalcare Group Plc worth?
The market values Animalcare Group Plc at about 233M GBX (market capitalisation, as of Sep 24, 2026). Per share that is £3.35; our models calculate a fair value of £3.44 per share.
What do the bullish and bearish scenarios say about ANCR?
Our models span a range for Animalcare Group Plc: cautious scenario £2.42, base £3.44, optimistic £4.48 per share (as of Sep 24, 2026, price £3.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ANCR?
Animalcare Group Plc trades at a price-to-earnings ratio of 47.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £3.44 is built from several models across several years. Other multiples: P/B 2.0, P/S 2.6, EV/EBITDA 18.6.
How solid is the balance sheet of Animalcare Group Plc (ANCR)?
Balance-sheet figures for Animalcare Group Plc (as of Sep 24, 2026): return on equity 4.5%, debt of 0.09 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is ANCR from its 52-week high?
Animalcare Group Plc trades at £3.35, at its 52-week high of £3.35 and 57% above the low of £2.14 (as of Jul 30, 2026). Distance from the high says nothing about value: that is what the fair value of £3.44 is for.
Which stocks are comparable to Animalcare Group Plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Animalcare Group Plc stock attractive at the current price?
The data as of Sep 24, 2026: price £3.35, calculated fair value £3.44 (+3%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANCR calculated?
We run Animalcare Group Plc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £3.44, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Animalcare Group Plc currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Animalcare Group Plc (ANCR)?
The latest price we hold is from Jul 30, 2026 and stands at £3.35. Our model-based fair value is £3.44, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Animalcare Group Plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (£2.42 to £4.48) leaves room in how you read the outcome.
Where does the earnings growth of Animalcare Group Plc (ANCR) come from?
Earnings per share at Animalcare Group Plc grew +19.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +20.7 %, EBIT margin −11.7 %, tax rate +0.8 %, residual (interest, one-offs) +11.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Animalcare Group Plc
How large is the market capitalisation of Animalcare Group Plc (ANCR)?
The market capitalisation of Animalcare Group Plc is 233M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Animalcare Group Plc (ANCR)?
The price-to-sales ratio of Animalcare Group Plc is 2.73 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Animalcare Group Plc (ANCR)?
Earnings per share at Animalcare Group Plc are £0.0700 (price ÷ EPS = P/E 47.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Animalcare Group Plc (ANCR)?
The dividend yield of Animalcare Group Plc is 0.7% (payout 31.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Animalcare Group Plc (ANCR)?
The net margin of Animalcare Group Plc is 5.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Animalcare Group Plc (ANCR)?
The return on equity (ROE) of Animalcare Group Plc is 4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Animalcare Group Plc (ANCR)?
On an EBIT basis the return on assets of Animalcare Group Plc is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Animalcare Group Plc (ANCR)?
The operating margin of Animalcare Group Plc is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Animalcare Group Plc (ANCR)?
Revenue at Animalcare Group Plc is growing +21.5% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Animalcare Group Plc (ANCR)?
Earnings per share at Animalcare Group Plc are growing −84.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Animalcare Group Plc (ANCR) carry?
The net debt of Animalcare Group Plc is 12.3M GBX (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Animalcare Group Plc in the live analysis
One click puts Animalcare Group Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
